for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Revance Therapeutics Inc

RVNC.OQ

Latest Trade

28.64USD

Change

-0.20(-0.69%)

Volume

144,623

Today's Range

27.92

 - 

29.04

52 Week Range

11.80

 - 

34.61

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
28.84
Open
28.75
Volume
144,623
3M AVG Volume
10.49
Today's High
29.04
Today's Low
27.92
52 Week High
34.61
52 Week Low
11.80
Shares Out (MIL)
66.55
Market Cap (MIL)
1,905.97
Forward P/E
-6.04
Dividend (Yield %)
--

Next Event

Q4 2020 Revance Therapeutics Inc Earnings Release

Latest Developments

More

Revance Therapeutics Sees Q4 Unaudited RHA Collection Rev Of $9.5 Mln To $10 Mln

FDA Defers Approval Of Daxibotulinumtoxina For Injection In Glabellar Lines Due To Covid-19 Related Travel Restrictions

Revance Reports Q3 2020 Financial Results

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Revance Therapeutics Inc

Revance Therapeutics, Inc. is a biotechnology company. The Company is focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The DaxibotulinumtoxinA for Injection combines a stabilizing peptide excipient with a purified botulinum toxin that does not contain human or animal-based components. It evaluates DaxibotulinumtoxinA for Injection in the full upper face, including glabellar lines, forehead lines and crow’s feet, as well as in three therapeutic indications: cervical dystonia, adult upper limb spasticity and plantar fasciitis. It has a portfolio of products and services for United States aesthetics practices, including the resilient hyaluronic acid (RHA) Collection of dermal fillers and HintMD fintech platform. The RHA Collection of dermal fillers is a filler for correction of dynamic facial wrinkles and folds. HintMD fintech platform includes integrated smart payment, subscription and loyalty digital services.

Industry

Biotechnology & Drugs

Contact Info

1222 Demonbreun Street, Suite 1001

NASHVILLE, TN

37203

United States

+1.510.7423400

http://www.revance.com/

Executive Leadership

Angus Charles Russell

Independent Chairman of the Board

Mark J. Foley

President, Chief Executive Officer, Director

Tobin C. Schilke

Chief Financial Officer

Abhay Joshi

Chief Operating Officer, President - R&D and Product Operations

Dwight Moxie

Senior Vice President, General Counsel, Corporate Secretary

Key Stats

1.82 mean rating - 11 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (USD)

2017

-4.010

2018

-3.940

2019

-3.670

2020(E)

-4.745
Price To Earnings (TTM)
--
Price To Sales (TTM)
445.22
Price To Book (MRQ)
5.11
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
47.57
LT Debt To Equity (MRQ)
47.57
Return on Investment (TTM)
-56.61
Return on Equity (TTM)
-50.94

Latest News

Latest News

BRIEF-Revance Announces Last Patient Enrolled in Modified JUNIPER Phase 2 Upper Limb Spasticity Trial

* REVANCE ANNOUNCES LAST PATIENT ENROLLED IN MODIFIED JUNIPER PHASE 2 UPPER LIMB SPASTICITY TRIAL OF DAXIBOTULINUMTOXINA FOR INJECTION

BRIEF-Revance Announces Positive Results In Two Phase 2A Studies For Treatment Of Forehead Lines And Crow’s Feet

* REVANCE ANNOUNCES POSITIVE RESULTS IN TWO PHASE 2A STUDIES OF DAXIBOTULINUMTOXINA FOR INJECTION FOR THE TREATMENT OF FOREHEAD LINES AND CROW’S FEET, RESPECTIVELY

BRIEF-Revance And Mylan To Advance Development Program For Biosimilar To Botox

* REVANCE AND MYLAN TO ADVANCE DEVELOPMENT PROGRAM FOR BIOSIMILAR TO BOTOX®

BRIEF-Revance Reports Agreement To Acquire HintMD

* REVANCE ANNOUNCES AGREEMENT TO ACQUIRE HINTMD AND ITS PROPRIETARY FINTECH PLATFORM FOR AESTHETIC PRACTICES

BRIEF-Revance Reports First Quarter 2020 Financial Results, Provides Corporate Update

* REVANCE REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS, PROVIDES CORPORATE UPDATE

BRIEF-Revance And Mylan Biosimilar To Botox Program Decision To Extend Beyond April 30, 2020

* REVANCE AND MYLAN BIOSIMILAR TO BOTOX® PROGRAM DECISION TO EXTEND BEYOND APRIL 30, 2020

BRIEF-Revance's Launch Of Rha Fillers, Hiring Pushed Back One Quarter Due To Covid-19

* REVANCE THERAPEUTICS INC - PDUFA TARGET ACTION DATE FOR DAXI IN GLABELLAR LINES OF NOV 25, 2020

BRIEF-Revance Reports Q4 Loss Per Share $0.99

* REVANCE REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS, PROVIDES CORPORATE UPDATE

BRIEF-Revance Announces Pricing Of $250 Million Of Convertible Senior Notes Due 2027

* REVANCE ANNOUNCES PRICING OF $250 MILLION OF CONVERTIBLE SENIOR NOTES DUE 2027

BRIEF-Revance Announces Proposed Private Offering Of $200 Mln Of Convertible Senior Notes Due 2027

* REVANCE ANNOUNCES PROPOSED PRIVATE OFFERING OF $200 MILLION OF CONVERTIBLE SENIOR NOTES DUE 2027 Source text for Eikon: Further company coverage:

BRIEF-Revance Therapeutics Announces Proposed Private Offering Of $200 Mln Of Convertible Senior Notes Due 2027

* REVANCE THERAPEUTICS INC - ANNOUNCES PROPOSED PRIVATE OFFERING OF $200 MILLION OF CONVERTIBLE SENIOR NOTES DUE 2027

Revance Therapeutics' Botox rival succeeds in late-stage trial

A potential rival for Allergan Plc's blockbuster Botox has passed a late-stage study, putting drug developer Revance Therapeutics Inc on course to file for U.S. marketing approval next year.

Revance Therapeutics' frown lines treatment succeeds in late-stage trial

Medical aesthetics company Revance Therapeutics Inc said on Tuesday that its long-acting injectable drug was successful in reducing moderate-to-severe frown lines in a late-stage study.

BRIEF-Revance Reports Qtrly Loss Per Share $0.97

* REITERATES ITS FINANCIAL GUIDANCE PROVIDED IN JANUARY 2018 Source text for Eikon: Further company coverage:

Mylan teams up with Revance on biosimilar for Botox

Mylan NV on Wednesday struck a licensing agreement with Revance Therapeutics Inc to develop a biosimilar of Allergan Plc's blockbuster Botox wrinkle treatment.

BRIEF-Revance Reports Qtrly Net Loss Per Share Attributable To Common Stockholders $1.14

* REVANCE THERAPEUTICS INC - REITERATES ITS FINANCIAL GUIDANCE PROVIDED IN JANUARY 2018

BRIEF-Revance Therapeutics, Mylan Ireland Enter Collaboration Deal‍

* REVANCE THERAPEUTICS SAYS CO, MYLAN IRELAND LIMITED ENTERED INTO COLLABORATION DEAL- SEC FILING

BRIEF-Revance Therapeutics Inc Announced Interim 8-Week Phase 2A Results For Rt002 In Treating Plantar Fasciitis

* REVANCE THERAPEUTICS INC - ANNOUNCED INTERIM 8-WEEK PHASE 2A RESULTS FOR RT002 IN TREATING PLANTAR FASCIITIS

BRIEF-Revance Provides Update On Anticipated Clinical Milestones And Financial Outlook For 2018

* REVANCE PROVIDES UPDATE ON ANTICIPATED CLINICAL MILESTONES AND FINANCIAL OUTLOOK FOR 2018

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up